Edge Rewrite
restyle Source code View original
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

N-Isopropyltryptamine

Add links
From Wikipedia, the free encyclopedia
(Redirected from N-isopropyltryptamine)

N-Isopropyltryptamine
Clinical data
Other namesNiPT; IPT; N-iP-T
Drug classSerotonin receptor agonist; Serotonin 5-HT2A receptor agonist
ATC code
  • None
Identifiers
  • N-[2-(1H-indol-3-yl)ethyl]propan-2-amine
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC13H18N2
Molar mass202.301 g·mol−1
3D model (JSmol)
  • CC(C)NCCC1=CNC2=CC=CC=C21
  • InChI=1S/C13H18N2/c1-10(2)14-8-7-11-9-15-13-6-4-3-5-12(11)13/h3-6,9-10,14-15H,7-8H2,1-2H3
  • Key:QOCRVKNKLPEDCZ-UHFFFAOYSA-N

N-Isopropyltryptamine (NiPT) is a serotonin receptor agonist of the tryptamine family.[1][2]

Use and effects

[edit]

According to Alexander Shulgin, no active dose level of NiPT has yet been found in humans.[1]

Pharmacology

[edit]

Pharmacodynamics

[edit]

NiPT acts as a potent full agonist of the serotonin 5-HT2A receptor, whereas it is inactive as an agonist of the serotonin 5-HT1A receptor.[2] The drug is also a weak serotonin reuptake inhibitor.[2]

Chemistry

[edit]

Analogues

[edit]

Analogues of NiPT include N-methyltryptamine (NET), N-ethyltryptamine, N-sec-butyltryptamine (NsBT), N-tert-butyltryptamine (NtBT), and diisopropyltryptamine (DiPT), among others.[1]

Derivatives

[edit]

Some derivatives of NiPT include 4-HO-NiPT, 5-HO-NiPT, and 5-MeO-NiPT, among others.[3][4][5][6] 5-MeO-NiPT is likewise a serotonin receptor agonist.[7][5][2] It is a potent full agonist or high-efficacy partial agonist of the serotonin 5-HT1A, 5-HT2A, 5-HT2B, and 5-HT2C receptors.[7][5][2] In contrast to 5-MeO-NMT and 5-MeO-NET, which are inactive in the test, 5-MeO-NiPT induces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents, and hence may be hallucinogenic in humans.[7][5] 4-HO-NiPT is also a serotonin receptor agonist and produces the head-twitch response in rodents as well.[6]

Society and culture

[edit]
[edit]

Canada

[edit]

NiPT is not a controlled substance in Canada as of 2025.[8]

See also

[edit]

References

[edit]
  1. 1 2 3 Alexander T. Shulgin, Ann Shulgin (1997). TiHKAL: The Continuation (1st ed.). Berkeley, CA: Transform Press. ISBN 978-0-9630096-9-2. OCLC 38503252. Retrieved 30 January 2025. The homologue with only one isopropyl group on the nitrogen, N-isopropyltryptamine or NIPT IPT, has been made according to the same recipe, with the indol-3-yl N-isopropylglyoxalylamide (mp 199–200 °C from methanol) obtained in a 98% yield, and the amine hydrochloride (mp 245–246 °C from benzene/methanol) obtained in a 60% yield. The free base distilled at 130–140 °C at 0.1 mm/Hg to give a fraction that spontaneously crystallized to a very hard solid. MS (in m/z): C4H10N+ 72 (100%); indolemethylene+ 131 (60%), 130 (32%); parent ion 202 (3%). No active level has yet been found in man, to my knowledge.
  2. 1 2 3 4 5 Blough BE, Landavazo A, Decker AM, Partilla JS, Baumann MH, Rothman RB (October 2014). "Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes". Psychopharmacology. 231 (21). Berlin: 4135–4144. doi:10.1007/s00213-014-3557-7. PMC 4194234. PMID 24800892.
  3. ↑ Araújo AM, Carvalho F, Bastos ML, Guedes de Pinho P, Carvalho M (August 2015). "The hallucinogenic world of tryptamines: an updated review" (PDF). Archives of Toxicology. 89 (8): 1151–1173. Bibcode:2015ArTox..89.1151A. doi:10.1007/s00204-015-1513-x. PMID 25877327.
  4. ↑ Laban U, Naeem M, Chadeayne AR, Golen JA, Manke DR (March 2023). "Synthesis and structure of 4-hy-droxy-N-iso-propyl-tryptamine (4-HO-NiPT) and its precursors". Acta Crystallographica Section E: Crystallographic Communications. 79 (Pt 4): 280–286. Bibcode:2023AcCrE..79..280L. doi:10.1107/S2056989023002098. PMC 10088304. PMID 37057027.
  5. 1 2 3 4 Puigseslloses P, Nadal-Gratacós N, Ketsela G, Weiss N, Berzosa X, Estrada-Tejedor R, et al. (August 2024). "Structure-activity relationships of serotonergic 5-MeO-DMT derivatives: insights into psychoactive and thermoregulatory properties". Molecular Psychiatry. 29 (8): 2346–2358. doi:10.1038/s41380-024-02506-8. PMC 11412900. PMID 38486047.
  6. 1 2 Sherwood AM, Burkhartzmeyer EK, Williamson SE, Baumann MH, Glatfelter GC (January 2024). "Psychedelic-like Activity of Norpsilocin Analogues". ACS Chemical Neuroscience. 15 (2): 315–327. doi:10.1021/acschemneuro.3c00610. PMC 10797613. PMID 38189238.
  7. 1 2 3 Glatfelter GC, Clark AA, Cavalco NG, Landavazo A, Partilla JS, Naeem M, et al. (December 2024). "Serotonin 1A Receptors Modulate Serotonin 2A Receptor-Mediated Behavioral Effects of 5-Methoxy-N,N-dimethyltryptamine Analogs in Mice". ACS Chemical Neuroscience. 15 (24): 4458–4477. doi:10.1021/acschemneuro.4c00513. PMID 39636099.
  8. ↑ "Controlled Drugs and Substances Act". Department of Justice Canada. Retrieved 19 January 2026.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=N-Isopropyltryptamine&oldid=1338634874"